Furthermore, all TSCC/BOTSCC cell lines, with/without FGFR or PI3K mutations, were sensitive to PI3K and FGFR inhibitors and those with such mutations were not necessarily more sensitive or resistant to the inhibitors, similar to that reported for other tumor types (35, 42, 43, 46–53). This evidence concerns the gene PIK3CA and neoplasm.